BioWorld - Friday, December 26, 2025 To read the full story, subscribe or sign in. Cancer New CDK inhibitors disclosed in Adlai Nortye patent Dec. 2, 2025 Adlai Nortye Biopharma Co. Ltd. and Adlai Nortye Pte Ltd. have divulged cyclin-dependent kinase 2 (CDK2) and/or CDK4 and/or CDK6 inhibitors reported to be useful for the treatment of inflammatory disorders, immunological disorders and cancer. BioWorld ScienceCancerPatents